Clinical Trial Update: Dose-Escalating Study of Pfs230D1 in Combination With R21 in Matrix-M in African Adults [Phase 1]

View source ↗

Summary

A Phase 1 dose-escalation trial evaluating Pfs230D1 with the R21 malaria vaccine in Matrix-M adjuvant in African adults has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malaria

Drugs mentioned

• Matrix-M adjuvant (Matrix-M)
• Pfs230D1 (Pfs230D1)
• R21 vaccine (R21)

Snippet

Sponsor: Serum Institute of India Pvt. Ltd. | Conditions: Prevention of Malaria Transmission and Clinical Malaria | Phase 1 | Status: COMPLETED